United States: Genetic Testing, Genome Sequencing, And The FDA

In recent years, the Food and Drug Administration has been struggling with how to adapt the regulatory paradigm for in vitro diagnostic devices (IVDs) – any test that detects a disease, condition, or infection – to the rapidly developing world of genetic and genomic testing services. As the health care system continues to move towards the White House's vision of precision medicine, FDA appears to be doing its part by exercising its medical device authorities over emerging genetic and genomic IVDs in a risk-based and scientifically driven manner. This blog post will highlight some recent actions taken by the Agency that relate to genetic and genomic testing, as well as some ongoing activities in this area that we will continue to monitor for our readers.

Regulatory Actions on Autosomal Carrier Screening Gene Mutation Tests

Early this year, FDA authorized the marketing of an autosomal carrier screening gene mutation test for Bloom Syndrome, submitted by 23andMe as a de novo classification request. The company filed this de novo request because there was no legally marketed device upon which it could rely for a showing of substantial equivalence; such a request triggers FDA's review of available science and other data provided by the applicant so that it can determine whether to classify the novel device as low-risk (Class I) or moderate-risk (Class II). In the case of 23andMe's carrier screening test, FDA concluded that the device should be regulated as Class II subject to special controls. 23andMe launched its new Personalized Genome Service direct-to-consumer product last month, touting itself as the "first and only company to receive FDA authorization to market a direct-to-consumer genetic test."

As a direct consequence of its review of 23andMe's data and the Agency's de novo classification decision, in late October FDA published two orders that apply to all "autosomal recessive carrier screening gene mutation detection systems" going forward. Specifically, as noted above, this generic type of device has been classified into Class II (subject to special controls for medical devices) and also exempted from premarket notification requirements (also known as a 510(k) notification). As a consequence, companies that may want to market similar products can do so without filing any sort of documentation with the Agency before launch, as long as all of the general controls for medical devices (registration and listing with FDA, labeling, quality systems compliance, etc.) and all of the relevant special controls for this particular device type have been met.

The genetic test device is defined as: "Autosomal recessive carrier screening gene mutation detection system is a qualitative in vitro molecular diagnostic system used for genotyping of clinically relevant variants in genomic DNA isolated from human peripheral whole blood or saliva specimens intended for prescription use or over-the-counter use. The device is intended for autosomal recessive disease carrier screening in adults of reproductive age. The device is not intended for copy number variation, cytogenetic, or biochemical testing." What is most interesting about this new device classification is the detailed and extensive "special controls" that have been put into place by the Agency to provide reasonable assurance of its safety and effectiveness. The new classification regulation, which will be codified at 21 C.F.R. § 866.5940, includes a list of 6 special controls with which any marketer of this type of product must comply. They set forth requirements for instructions for how an OTC user can obtain access to genetic counseling services; the type of specimen collection devices that are permissible for use with the test; specific labeling information, warning statements, and how to present certain data about the test such as its clinical validity and the results of user comprehension studies when the device is offered OTC; performance specifications; and limits on distribution.

Clinical Laboratory Tests and a New Regulatory Paradigm

The final control in the new regulation described above – distribution limits for a marketed autosomal recessive carrier screening test – specifies that only the manufacturer of the test, the manufacturer's subsidiaries, and clinical laboratories regulated under CLIA may lawfully distribute the product. Many of FDA's public health concerns about the widespread availability of direct-to-consumer genetic tests through outlets such as Amazon.com (as communicated by the Agency in a slew of enforcement-like letters sent to manufacturers in 2010) would be mitigated by these distribution limits and other special controls for the device. As other types of genetic and genomic test systems receive FDA's blessing, we expect to see similar controls established to ensure safety and effectiveness.

In response to the significant growth of this industry with respect to the complexity of the tests, the number of players that do not meet the traditional form of a clinical laboratory, and the number of potential patients being affected, and following its 2010 enforcement sweep, FDA held public meetings and requested stakeholder input on how to modernize its regulation of this specific class of IVDs. In late 2014, FDA released a proposed framework for regulating laboratory-developed tests (LDTs) intended to clarify that only IVDs intended for clinical use and also designed, manufactured, and used within a single laboratory will continue to be subject to enforcement discretion for premarket review and compliance with quality systems rules. Certain moderate-risk and high-risk tests, however, will become subject to those regulatory requirements over time using a phased-in approach that would begin after FDA finalizes the LDT framework and guidance documents.

The LDT proposal has generated significant controversy, including several competing alternative proposals from interested parties, and there has been no indication from FDA on a time frame for a final policy. In the absence of final action agency here, clinical laboratories are feeling uncertain about how to move forward with introducing new tests and those concerns about a lack of clarity have started to be expressed to the Agency. So we would expect some indication from FDA in the near future about its plans surrounding the proposed regulatory framework for LDTs. It is also worth noting that after a downtick in letters going from FDA to manufacturers of genetic/genomic tests during the past 12-15 months, we have in the past month or so noticed a renewed interest from the Agency in communicating to those companies that their activities may be in violation of the regulatory requirements for diagnostic tests.

High-Throughput Genome Sequencing and Clinical Validity

Last but not least, this week FDA is hosting two days of workshops to collect more information from researchers and business alike regarding how to advance next-generation sequencing (NGS) technologies into clinical practice, building on similar meetings held in February 2015 and in prior years. NGS is a term used to describe new technologies that allow rapid sequencing of large segments of an individual's DNA or even their entire genome – potentially leading to the ultimate form of personalized medicine. The challenges faced by both FDA and developers of these products derive from the fact that a single NGS test can yield information about millions of genetic variations in a single individual and, accordingly, the diagnosis or risk assessment of multiple diseases or conditions. This makes it impracticable, if not impossible, for a developer to collect data on every single variant and its potential clinical relevance.

At the workshops, Agency officials and scientists working on NGS technologies in academic, commercial, and clinical labs will discuss the pros and cons of various analytical standards approaches and the possibility of relying on publicly available, independently curated genetic databases in order to establish clinical relevance of a given test (as FDA did for two cystic fibrosis sequencing assays cleared in 2013). The ultimate goal of these workshops is to inform FDA as it develops a "flexible, adaptive regulatory approach" to NGS tests that also ensures "patients receive accurate and meaningful results, while accommodating innovation in test development," as the Agency notes in one of its discussion papers for this week.

Besides the regulatory challenges facing developers and users of cutting edge genetic and genomic tests, pricing and reimbursement strategies are also being assessed for their impact on the uptake of personalized medicine. My health care colleagues are monitoring those issues and have previously discussed the implementation of Alternative Payments Models to advance personalized medicine.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.